North America and Europe Women's Health Market - Industry Trends and Forecast to 2031
Europe women’s health market is expected to reach USD 5,384.03 million by 2031, from USD 3,280.54 million in 2023 growing at the CAGR of 6.7% in the forecast period of 2024 to 2031.
North America women’s health market is expected to reach USD 11,108.64 million by 2031 from USD 5,841.61 million in 2023, growing at a CAGR of 9.3% in the forecast period of 2024 to 2031.
Market SegmentationNorth America and Europe Women's Health Market, By Treatment (Drugs and Devices), Indication (Cancer, Reproductive Health, Urological Disorders, Hypothyroidism, Post-Menopausal Syndrome, and Others), Delivery Mode (Prescription and Over The Counter), Drug Type (Branded and Generic), Care Type (General Healthcare & Wellness, Pregnancy & Nursing Care, Pelvic & Uterine Healthcare, and Others), End User (Hospitals and Clinics, Gynecology Centers, Homecare Settings, Homecare Setting, Research Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, Online Sales, and Others), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, and Rest of Europe) - Industry Trends and Forecast to 2031
Overview of Europe Women’s Health Market Dynamics
Driver• Rising rates of chronic debilitating conditions among women
Restrain
• Adverse effects associated with certain products
Opportunity • Growing awareness and acceptance of fertility treatments
Market PlayersSome of the major players operating in the North America and Europe women’s health market are:
• Pfizer Inc.
• Lilly
• Novartis AG
• AbbVie Inc.
• GSK plc.
• Abbott
• Noven Pharmaceuticals, Inc.
• Lupin
• Vertical Pharmaceuticals, LLC
• Veru Inc.